Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

Study acronym: DETENTE-1
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to compare the effectiveness of several treatment regimens for stage I triple negative breast cancer before surgery. The main question it aims to answer is if these regimens will reduce or completely remove all cancer cells before surgery.
Trial Details
NCT Number NCT07786428
Lead Sponsor University of Texas Southwestern Medical Center
Conditions
(from sponsor)		 Triple-Negative Breast Cancer (TNBC)
Related terms Triple Negative Breast Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov